Literature DB >> 25500257

Association between interleukin 1 receptor antagonist gene 86-bp VNTR polymorphism and sepsis: a meta-analysis.

Fang Fang1, Jian Pan1, Yiping Li1, Lixiao Xu1, Guanghao Su1, Gang Li1, Jian Wang2.   

Abstract

OBJECTIVE: Many studies have focused on the relationship between interleukin 1 receptor antagonist (IL1RN) gene 86-bp VNTR polymorphism and sepsis, but the results remain inconsistent. Thus, a meta-analysis was carried out to derive a more precise estimation of the association between IL1RN 86-bp VNTR polymorphism and risk of sepsis and sepsis-related mortality.
METHODS: Relevant publications were searched in several widely used databases and six eligible studies were included in the meta-analysis. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to evaluate the strength of the association between IL1RN 86-bp VNTR polymorphism and risk of sepsis and sepsis-related mortality.
RESULTS: Significant associations between IL1RN 86-bp VNTR polymorphism and sepsis risk were observed in both overall meta-analysis for L2 versus 22 (OR=0.75, 95% CI=0.59-0.94) and severe sepsis subgroup for LL+L2 versus 22 (OR=0.67, 95% CI=0.47-0.93). L stands for long alleles containing three to six repeats; 2 stands for short allele containing two repeats. However, no significant sepsis mortality variation was detected for all genetic models.
CONCLUSIONS: According to the results of our meta-analysis, the IL1RN 86-bp VNTR polymorphism probably associates with sepsis risk but not with sepsis-related mortality.
Copyright © 2014. Published by Elsevier Inc.

Entities:  

Keywords:  Interleukin 1 receptor antagonist; Meta-analysis; Mortality; Polymorphism; Sepsis

Mesh:

Substances:

Year:  2014        PMID: 25500257     DOI: 10.1016/j.humimm.2014.12.013

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  1 in total

1.  Association of 86 bp variable number of tandem repeat (VNTR) polymorphism of interleukin-1 receptor antagonist (IL1RN) with susceptibility and clinical activity in rheumatoid arthritis.

Authors:  S Ramírez-Pérez; M Salazar-Páramo; S Pineda-Monjarás; U De la Cruz-Mosso; J Hernández-Bello; G E Martínez-Bonilla; A L Pereira-Suárez; J F Muñoz-Valle
Journal:  Clin Rheumatol       Date:  2017-03-25       Impact factor: 2.980

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.